| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,201,243 | -2,286,870 | -3,066,589 | -4,489,028 |
| Amortization of debt discount and closing costs | NaN | 0 | 0 | 771,437 |
| Stock-based compensation expense | 17,386 | 611,839 | 6,040 | 24,485 |
| Stock-based compensation recapture expense | NaN | 0 | 0 | -86,617 |
| Common stock issued for services | 5,000 | 126,140 | NaN | NaN |
| Other receivables | NaN | 53,082 | NaN | NaN |
| Income receivables | -53,082 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | -232,398 | 313,178 | 1,135,815 | -441,707 |
| Change in operating lease liabilities | NaN | NaN | NaN | 0 |
| Operating lease right of use assets | NaN | NaN | NaN | 0 |
| Accounts payable and accrued expenses | -307,267 | -920,261 | 1,211,849 | -88,444 |
| Net cash used in operating activities | -2,200,644 | -2,835,412 | -2,984,515 | -3,426,460 |
| Proceed from sale of short-term investments | 4,000,000 | NaN | NaN | NaN |
| Borrowings on short-term notes payable | NaN | -167,488 | 394,836 | 2,228,563 |
| Net cash provided by investing activities | 4,000,000 | NaN | NaN | NaN |
| Payments on short-term notes payable | 171,214 | 0 | 3,000,000 | 328,528 |
| Net proceeds from issuance of preferred stock and warrants | NaN | 0 | 15,019,700 | NaN |
| Net proceeds from issuance of common stock | 79,210 | -1,140 | 0 | 2,635,330 |
| Net cash (used) provided by financing activities | -92,004 | -168,628 | 12,414,536 | 4,535,365 |
| Net increase (decrease) in cash and cash equivalents | NaN | -3,004,040 | 9,430,021 | 1,108,905 |
| Net increase in cash and cash equivalents | 1,707,352 | NaN | NaN | NaN |
| Cash and cash equivalents at beginning of period | 4,399,726 | 11,403,766 | 864,840 | NaN |
| Cash and cash equivalents at end of period | 6,107,078 | 8,399,726 | 11,403,766 | NaN |
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)